The Relationship Between Myd88 And Neo-Adjuvant Chemotherapy Of Breast Cancer

Objective:Myeloid differentiation factor-88 (MyD88) is closely related to the tumorigenesis, development and chemotherapy resistance in some kinds of cancer. The article is intended to detect the expression of MyD88 in breast cancer tissues and to preliminarily probe the potential value of MyD88 in predicting the therapeutic response of breast carcinoma to chemotherapy.Methods:Fifty-nine patients with breast invasive ductal carcinoma hospitalized in Chongqing Cancer Hospital from 2009.6 to 2013.6 were identified. The diagnosis was confirmed by histopathological examination and all patients received 4 cycles of TAC neoadjuvant chemotherapy. Their gene expression level of Topo â…¡, MDR 1, GST-Ï€ and p53 were reviewed. The expression of MyD88 was detected by immunohistochemical staining and the therapeutic response was evaluated by using the pathological, clinical or pCR standard. The relationship between MyD88 expression and the therapeutic response to chemotherapy was analyzed. The correlative analysis between MyD88and Topo â…¡, MDR 1, GST-Ï€ or p53 was performed.Results:MyD88 expressed in some patients with breast cancer and the positive rate was 47.46%. The expression of MyD88 was correlated with the pathological response of breast cancer tissue to chemotherapy (P=0.045). And the efficacy of chemotherapy in MyD88 positive patients was significantly poor than that in negative patients. The expression status of MyD88 was also associated with Topo â…¡ (P=0.007) and p53 (P=0.041) gene, genes related to some anthracycline-resistant events.Conclution:MyD88 expressed in tumor tissue of some patients with breast cancer. The expression status of MyD88 possesses potential value in predicting the therapeutic response of breast carcinoma to TAC neoadjuvant chemotherapy. MyD88 may correlate to the resistance of anthracycline based chemotherapy.